Kalaris Therapeutics
KLRS
71 hedge funds and large institutions have $854M invested in Kalaris Therapeutics in 2020 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 12 closing their positions.
171% more call options, than puts
Call options by funds: $19K | Put options by funds: $7K
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
51% more capital invested
Capital invested by funds: $566M → $854M (+$288M)
16% more funds holding
Funds holding: 61 → 71 (+10)
0.17% more ownership
Funds ownership: 1.4% → 1.56% (+0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIG
American International Group
New York
|
+$30.1M |
| 2 |
BlackRock
New York
|
+$21.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$16.9M |
| 5 |
TG
TCW Group
Los Angeles,
California
|
+$7.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$8.97M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$8.57M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$5.06M |
| 4 |
Goldman Sachs
New York
|
-$1.07M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$1.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
76
CAAS Capital Management
New York
| – | -$688K | -1,087 | Closed |
|
|
ZP
77
Zimmer Partners
New York
| – | -$688K | -1,087 | Closed |
|
|
MFS
78
Mirabella Financial Services
London,
United Kingdom
| – | -$462K | -730 | Closed |
|
|
SSA
79
Schonfeld Strategic Advisors
New York
| – | -$366K | -578 | Closed |
|
80
Jane Street
New York
| – | -$311K | -492 | Closed |
|
|
SO
81
STRS Ohio
Columbus,
Ohio
| – | -$123K | -196 | Closed |
|
|
CG
82
Cutler Group
San Francisco,
California
| – | -$13K | -22 | Closed |
|
83
Simplex Trading
Chicago,
Illinois
| – | -$3.85K | -5 | Closed |
|
KLRS Hedge Fund Activity: Q4 2020 in Review
71 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q4 2020, worth a combined $854M — up 51% from $566M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new KLRS positions and 12 closed out — a net gain of 10 holders — while 23 added to existing stakes and 14 trimmed.
The largest buyer was American International Group, adding an estimated $30.1M. The largest seller was Sectoral Asset Management, cutting an estimated $8.97M.
- 71 institutional investors held Kalaris Therapeutics (KLRS) as of Q4 2020, up from 61 in Q3 2020.
- Funds reported $854M of Kalaris Therapeutics stock for Q4 2020, up 51% quarter-over-quarter.
- 22 funds opened new Kalaris Therapeutics positions in Q4 2020 and 12 closed out, a net change of +10 holders.
- The largest Kalaris Therapeutics buyer in Q4 2020 was American International Group, an estimated $30.1M added.
- The largest Kalaris Therapeutics seller in Q4 2020 was Sectoral Asset Management, an estimated $8.97M sold.
Based on aggregated 13F filings for Q4 2020.